Le Lézard
Classified in: Health, Science and technology, Covid-19 virus
Subject: Product/Service

University of Adelaide Begins Human Trial of Omicron COVID Vaccine Booster Using PharmaJet Needle-free System


PharmaJet®, a company that has developed and commercialized a needle-free platform to more effectively administer drugs and biologics announced that its partner, University of Adelaide, has started a human trial of a DNA-based COVID-19 vaccine booster using the PharmaJet Tropis® Needle-free Injection System (NFIS).

The DNA-vaccine booster is one of the few vaccines worldwide targeting the Omicron variant, rather than the original strain of the virus. As DNA vaccines can be modified easily the vaccine can be quickly adapted to future variants. Lead investigator, Associate Professor Branka Grubor-Bauk, head of Viral Immunology at the University of Adelaide's Adelaide Medical School commented, "We need to continue developing 'next generation' COVID-19 vaccines because the virus will continue to mutate, particularly in countries with low vaccination rates and high rates of uncontrolled transmission." The vaccine is being exclusively administered using the PharmaJet Tropis® NFIS, which was chosen due to the data from numerous published preclinical and clinical studies demonstrating improved immunogenicity when administering DNA-vaccines.1

Chris Cappello, President and CEO, PharmaJet commented, "We are pleased to be partnering with the University of Adelaide as they begin their Omicron COVID-19 booster vaccine trials. Our partners have published 11 studies comparing delivery methods for DNA vaccines that demonstrate increased immunogenicity when using the PharmaJet Systems."

For more information about PharmaJet visit www.pharmajet.com.

Refer to Instructions for Use to ensure safe injections and to review risks.

1 Data on file

About PharmaJet

PharmaJet's mission is to enable greater access to life improving pharmaceuticals. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet's Needle-free Injection Systems provide increased vaccine effectiveness, a preferred patient and caregiver experience, and a proven path to market. They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections. For more information visit www.pharmajet.com. Follow us on LinkedIn.


These press releases may also interest you

at 03:14
The Walt Disney Company today forced a channel blackout on DISH TV and SLING TV, affecting favorites such as ESPN, FX, Disney Channel, Freeform and National Geographic, as well as ABC locals in eight markets. The media conglomerate declined DISH's...

30 sep 2022
The "Humanoid Robot Market by Component and Geography - Forecast and Analysis 2022-2026" report has been added to Technavio's offerings. The humanoid robot market is estimated to grow by USD 9.74 billion from 2021 to 2026. In addition, the growth...

30 sep 2022
LAS VEGAS, Sept. 30, 2022 The Kanpai Pandas are excited to announce our newest sponsored athlete, Roy Jones Jr.! Roy has world titles at middleweight, super middleweight, light heavyweight, and heavyweight and has been the only boxer in history to...

30 sep 2022
The Military Robots Market report has been added to Technavio's offering. The military robots market value is anticipated to grow by USD 8.19 billion, at a CAGR of 8.15% during the forecast period....

30 sep 2022
The "Automotive Active Aerodynamics System Market by Application (Mid-sized vehicles and High performance vehicles) and Geography (North America, Europe, APAC, Middle East and Africa, and South America) - Forecast and Analysis 2022-2026" report has...

30 sep 2022
The Process Automation And Instrumentation Market report has been added to Technavio's offering. With ISO 9001:2015 certification, Technavio is proudly partnering with more than 100 Fortune 500 companies for over 16 years....



News published on 16 august 2022 at 11:10 and distributed by: